OLD Mission Capital LLC Purchases New Shares in Addex Therapeutics Ltd (NASDAQ:ADXN)

OLD Mission Capital LLC purchased a new stake in Addex Therapeutics Ltd (NASDAQ:ADXNGet Rating) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 31,134 shares of the company’s stock, valued at approximately $36,000. OLD Mission Capital LLC owned about 0.29% of Addex Therapeutics at the end of the most recent quarter.

Addex Therapeutics Trading Up 1.7 %

NASDAQ ADXN opened at $0.78 on Monday. The firm has a market capitalization of $8.49 million, a P/E ratio of -0.22 and a beta of 1.94. The business has a fifty day simple moving average of $0.83 and a 200 day simple moving average of $1.76. Addex Therapeutics Ltd has a 12 month low of $0.64 and a 12 month high of $8.04.

Addex Therapeutics (NASDAQ:ADXNGet Rating) last announced its earnings results on Friday, November 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.56). Addex Therapeutics had a negative return on equity of 166.17% and a negative net margin of 1,315.84%. The firm had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.23 million. As a group, sell-side analysts predict that Addex Therapeutics Ltd will post -2.66 EPS for the current fiscal year.

Addex Therapeutics Company Profile

(Get Rating)

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors.

Featured Articles

Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.